Who
Sean Brynjelsen
President & CEO
Company insider
Files Form 4 as: President & CEO, Eton Pharmaceuticals; EVP, Business Development, Sagent Pharmaceuticals.
In numbers
- Trades disclosed
- 56
- Buys
- 7
- Sells
- 6
- Bought
- $264K
- Sold
- $23.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Apr 2016
- Last trade
- 20 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 20 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.8M47,307 at $60.17 | filing |
| 20 Aug 2026filed 20 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.2M36,373 at $61.11 | filing |
| 20 Aug 2026filed 20 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $456K7,342 at $62.12 | filing |
| 20 Aug 2026filed 20 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.8M47,307 at $60.17 | filing |
| 20 Aug 2026filed 20 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.2M36,373 at $61.11 | filing |
| 20 Aug 2026filed 20 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $456K7,342 at $62.12 | filing |
| 19 Aug 2026filed 20 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $562K8,978 at $62.65 | filing |
| 19 Aug 2026filed 20 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $562K8,978 at $62.65 | filing |
| 31 Jul 2026filed 4 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —128,985 at $0.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —128,985 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $274K200,000 at $1.37 | filing |
| 14 Jul 2026filed 14 Jul 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —200,000 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —200,000 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $274K200,000 at $1.37 | filing |
| 12 Jul 2026filed 14 Jul 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —27,500 | filing |
| 12 Jul 2026filed 14 Jul 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,500 at $0.00 | filing |
| 12 Jul 2026filed 14 Jul 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,500 at $0.00 | filing |
| 12 Jul 2026filed 14 Jul 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —27,500 | filing |
| 28 May 2026filed 29 May 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $3.8M119,852 at $31.88 | filing |
| 28 May 2026filed 29 May 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $4,835148 at $32.67 | filing |
News
Contrasting Eton Pharmaceuticals (NASDAQ:ETON) and Biofrontera (NASDAQ:BFRI)ETON · themarketsdaily.com · 24 Oct 2026Eton (NASDAQ: ETON) secures LIBERVANT license with milestones up to $47.5 millionETON · themarketsdaily.com · 14 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmETON · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Sean Brynjelsen; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.